MB11 (nivolumab biosimilar)
/ Insud Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 13, 2026
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
(clinicaltrials.gov)
- P3 | N=632 | Recruiting | Sponsor: mAbxience Research S.L. | Not yet recruiting ➔ Recruiting
Enrollment open • Mucosal Melanoma • Oncology • Solid Tumor • BRAF
October 29, 2025
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
(clinicaltrials.gov)
- P3 | N=632 | Not yet recruiting | Sponsor: mAbxience Research S.L.
New P3 trial • Melanoma • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1